Unresectable Hepatocellular Carcinoma Market Analysis, Growth Drivers, Top Players And Outlook 2033

The unresectable hepatocellular carcinoma market size has grown rapidly in recent years. It will grow from $1.75 billion in 2023 to $1.96 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to chemotherapy advances, clinical trial outcomes, liver transplantation limitations, increased cancer cases, expanded access to therapies.

The unresectable hepatocellular carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.64 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to healthcare policy changes, patient stratification strategies, real-world evidence utilization, patient advocacy and awareness, economic and dynamics. Major trends in the forecast period include precision medicine and biomarkers, real-world evidence and data integration, multidisciplinary approaches, global clinical trials and collaborations, patient-centric care.

Market Overview -
Unresectable hepatocellular carcinoma refers to an aggressive tumor that typically develops alongside cirrhosis and chronic liver disease. The treatment for unresectable hepatocellular carcinoma is surgical resection, liver transplant, ablation, and embolization.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp

The Rising Prevalence Of Liver Cancer Propels Growth In The Unresectable Hepatocellular Carcinoma Market
The increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market going forward. Liver cancer refers to the healthy, functioning cells of the liver being taken over by tumor cells as they start to develop uncontrollably. Unresectable hepatocellular carcinoma is a type of cancer treated by liver transplantation and radiofrequency ablation. For instance, In October 2022, according to the Journal of Hepatology, a Switzerland-based peer-reviewed scientific journal, globally, 830,200 people lost their lives to liver cancer by the year 2020. and there will probably be 1.4 million new cases of liver cancer diagnosed between 2020 and 2040, an increase of 55.0% in the number of new cases per year. Further, 1.3 million people will succumb to liver cancer in 2040, 56.4% more than in 2020. Therefore, the increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market.

Competitive Landscape -
Major companies operating in the unresectable hepatocellular carcinoma market report are Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.

Product Innovations Drive Growth In The Unresectable Hepatocellular Carcinoma Market
Product innovations are a key trend gaining popularity in the unresectable hepatocellular carcinoma market. Major companies operating in the unresectable hepatocellular carcinoma market are adopting innovative products to sustain their position in the market. For instance, in October 2022, AstraZeneca, a UK-based pharmaceutical and biotechnology company, launched FDA-approved Imjudo (tremelimumab) in combination with Imfinzi in the US for patients with unresectable liver cancer. The new treatment, known as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), consists of a single dosage of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500 mg every four weeks. Patients who received Imjudo and Imfinzi together had a 22% lower chance of passing away than those who received sorafenib.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/unresectable-hepatocellular-carcinoma-global-market-report

Key Segments -
The unresectable hepatocellular carcinoma market covered in this report is segmented -
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.